Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of the adenosine receptor signaling pathway. The adenosine receptor pathway is the series of molecular signals generated as a consequence of an adenosine receptor binding to one of its physiological ligands. [GOC:dph]
Negative regulation of adenosine receptor signaling pathway involves a complex interplay of molecular mechanisms that fine-tune the cellular response to adenosine. This process is essential for maintaining cellular homeostasis and preventing overstimulation by adenosine, a ubiquitous nucleoside with diverse physiological roles. Adenosine receptors (ARs) are G protein-coupled receptors (GPCRs) that mediate the effects of adenosine. There are four main subtypes of ARs: A1, A2A, A2B, and A3. These receptors are widely expressed throughout the body and are involved in a variety of physiological processes, including neurotransmission, cardiovascular function, inflammation, and immune response. Negative regulation of AR signaling can occur at various levels:
**1. Receptor Desensitization:** This is a rapid and transient process that reduces receptor responsiveness to adenosine. It involves phosphorylation of the receptor by specific kinases, such as GRKs (G protein-coupled receptor kinases), followed by binding of arrestins, proteins that sterically hinder G protein coupling and promote receptor internalization. Internalized receptors can be either recycled back to the cell surface or degraded.
**2. G Protein Regulation:** The activity of G proteins, which mediate signal transduction from ARs, can be regulated by several factors, including:
* **RGS proteins (Regulators of G protein signaling):** These proteins accelerate the hydrolysis of GTP by Gα subunits, effectively terminating signaling.
* **G protein-coupled receptor kinases (GRKs):** These kinases phosphorylate the activated Gα subunit, reducing its affinity for the receptor and promoting its dissociation.
* **Inhibitory G proteins:** Some GPCRs, including certain A1 receptors, couple to inhibitory G proteins (Gi/o), which can suppress downstream signaling pathways.
**3. Second Messenger Modulation:** Adenosine signaling often involves the generation of second messengers, such as cAMP (cyclic AMP), which can activate downstream effectors, including protein kinases. Negative regulation can involve the modulation of these second messengers:
* **Phosphodiesterases (PDEs):** These enzymes degrade cAMP, reducing its levels and attenuating downstream signaling.
* **Protein phosphatases:** These enzymes dephosphorylate signaling proteins, reversing their activation and reducing their activity.
**4. Transcriptional Regulation:** Long-term regulation of AR signaling involves the modulation of gene expression. This can be achieved through:
* **MicroRNAs (miRNAs):** These small non-coding RNAs can suppress the expression of genes involved in adenosine signaling.
* **Transcription factors:** Transcription factors can bind to specific DNA sequences and regulate the expression of AR genes or genes encoding proteins involved in AR signaling.
**5. Cross-talk with other Signaling Pathways:** Adenosine signaling can interact with other signaling pathways, leading to both positive and negative regulation. For example, adenosine signaling can be modulated by the activity of the sympathetic nervous system, inflammatory cytokines, and growth factors.
**6. Receptor Downregulation:** Prolonged exposure to adenosine can lead to a decrease in the number of ARs at the cell surface. This process involves the internalization and degradation of receptors, effectively reducing the overall responsiveness to adenosine.
**In summary,** negative regulation of adenosine receptor signaling pathway is a complex and multi-faceted process involving a combination of molecular mechanisms. These mechanisms ensure that the cellular response to adenosine is appropriately regulated, preventing overstimulation and maintaining cellular homeostasis. This delicate balance is essential for a wide range of physiological functions.'
"
Protein | Definition | Taxonomy |
---|---|---|
Adenosine deaminase | An adenosine deaminase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00813] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
9-(2-hydroxy-3-nonyl)adenine | 9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase | ||
coformycin | coformycins | EC 3.5.4.4 (adenosine deaminase) inhibitor | |
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
nebularine | nebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage. nebularine: structure | purine ribonucleoside; purines D-ribonucleoside | fungal metabolite |
9-(2-hydroxy-3-nonyl)adenine | (2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. | EHNA | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor |
9-(2-hydroxy-3-nonyl)adenine | (2S,3R)-EHNA : EHNA of absolute configuration 2S,3R. | EHNA | |
1-deazaadenosine | 1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source | ||
pentostatin | pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia. Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | coformycins | antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor |
8-azanebularine | 8-azanebularine: structure in first source | ||
msh, 4-nle-7-phe-alpha- | polypeptide | dermatologic drug |